Oral Mucositis Market Research Report Information By Cause (Chemotherapy, Radiotherapy, Hematopoietic Stem Cell Transplantation, and Others), By End-User (Hospitals, Dental Clinics, Oncology Hospitals, and Research Institutes), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Oral Mucositis Market Overview

Oral Mucositis Market Size was valued at USD 0.53 Billion in 2023. The oral mucositis market industry is projected to grow from USD 0.61 Billion in 2024 to USD 0.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.80% during the forecast period (2024 - 2032). Bad dental hygiene, an unhealthy lifestyle, and an increase in mouth and oral cavity infections are the key market drivers enhancing the market growth. However, increased and ongoing technological progress in diagnosis and treatment is also fueling the market's expansion.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Oral Mucositis Market Trends

• Rising prevalence of head and neck cancer is driving the market growth

Market CAGR for oral mucositis is being driven by the rising cases of head and neck cancer. About 150,000 and 750,000 Head and Neck Cancer instances are reported yearly, respectively, in the U.S. and Europe. In between 60 and 70 percent of these patients, severe oral mucositis (SOM) will occur. Radiation and cytotoxic chemotherapy medications have the side effect of causing oral mucositis. According to National Institutes of Health, over 400,000 people in the US are estimated to receive an oral mucositis diagnosis each year. The market for oral mucositis therapies is expanding alongside the worldwide cancer patient population. Oral mucositis therapy is becoming increasingly necessary, driving the market growth.

The development of collaborative tactics and increased clinical trials are improving the pipeline of oral mucositis treatments. The oral mucositis therapies pipeline included more than twenty medications in various stages of research as of March 2019 (in addition to nine commercialized treatments). The Phase 3 DOM-INNATE study for SGX942 (dusquetide) for the treatment of oral mucositis (OM) in patients with head and neck cancer (HNC) was completed in June 2020 by Soligenix, Inc., a biopharmaceutical company that develops and markets medications to treat rare diseases. Top-line results are anticipated in the fourth quarter of 2020 once enrollment is complete.

demand for diagnostic tools has increased due to an increasing number of programs launched by different organizations to enhance awareness about malignant tumor screening. During the research period, industry growth is anticipated to be boosted by partnerships and collaborations launched by the National Cervical Cancer Coalition, the WHO, the CDC, and the U.S. Preventive Services Task Force to increase cervical cancer screening. Additionally, several nations have taken action to increase screening for early screening and assist the current sufferers. For patients who need aid during treatment, the Indian government established Ayushman Bharat and the Prime Minister's National Relief Fund. Thus, driving the oral mucositis market revenue.

Oral Mucositis Market Segment Insights

Oral Mucositis Cause Insights

The oral mucositis market segmentation, based on cause, includes chemotherapy, radiotherapy, hematopoietic stem cell transplantation, and others. The chemotherapy segment dominated the market, accounting for 46.5% of market revenue (0.2 Billion). The sector for chemotherapy-induced oral mucositis is expanding along with the incidence of cancer patients worldwide and the number of chemotherapy treatments administered. Due to the radiation side effects and cytotoxic chemotherapy medications' oral mucositis-causing side effects, the market for chemotherapy-induced oral mucositis will be projected to grow significantly throughout the projection period. Furthermore, in 2022, the radiotherapy sector witnessed the fastest growth rate. Up to 91% of patients with head and neck cancer who receive radiotherapy have radiation-induced mucositis, linked to increased medical resource use and unnecessary medical spending. Patients who acquire radiation-induced mucositis should modify their diet to reduce incidental stress to the mucosa from chewing, similar to chemotherapy-induced mucositis.

Figure 1: Oral Mucositis Market, by Cause, 2024 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Oral Mucositis End-User Insights

 The oral mucositis market segmentation, based on end-user, includes hospitals, dental clinics, oncology hospitals, and research institutes. In 2022, the hospital category dominated the market. The strong presence of highly skilled experts using cutting-edge cancer diagnosis equipment in these settings can be credited with the growth. The rise in the frequency of cancer diagnoses made in hospitals directly results from the increased use of technologically advanced biopsies and diagnostic tools. Additionally, in 2022, the research institutes witnessed the fastest growth. The need for cancer diagnostics is growing globally due to the increased public knowledge of the disease. The desire of more people to find cancer as quickly as possible is boosting the sector. During the forecast period, the accessibility of several easy and non-invasive diagnostic instruments is anticipated to fuel the segment's rise.

Oral Mucositis Regional Insights

By region, the report offers market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American oral mucositis market area will dominate this market. An increase in head and neck cancer incidence will be the key factor driving the severe oral mucositis market's growth in the US throughout the forecast period. The 2021 report from the American Society of Clinical Oncology (ASCO) estimated that 66,630 people (48,740 men and 17,890 women) would be diagnosed with head and neck cancer. Additionally, throughout the forecast period, top players' focus on inorganic strategies and capital raising are predicted to be important drivers of market advancement.

Further, the leading countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: ORAL MUCOSITIS MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe’s oral mucositis market accounts for the second-largest market share. The rising incidence of cancer cases, expanding government backing, and expanded research activities to create cutting-edge medical treatment are driving the market in the region. Increased research and development efforts for creating fresh treatments for oral mucositis and technological advancements in biopharmaceuticals are other factors influencing the expansion of the market. Further, the German oral mucositis market held the largest market share, and the UK oral mucositis market was the rapidly-growing market in the European region.

The Asia-Pacific Oral Mucositis Market is estimated to expand at a rapid rate from 2024 to 2032. Due to factors like increasing prevalence, a sizable patient pool, proposed product launches, government support, improved healthcare infrastructure, increased awareness, an increase in well-equipped hospitals, increased research & development activities, technological advancements, and growing investments by market players for the creation of targeted therapies, thus, it is anticipated that growth would occur most quickly in the Asia-Pacific area. Moreover, China’s oral mucositis market held the largest market share, and the Indian oral mucositis market was the rapidly-growing market in the Asia-Pacific region.

Oral Mucositis Key Market Players & Competitive Insights

Leading market players are largely investing in research and development to expand their product lines, which will help the oral mucositis market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The oral mucositis industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the oral mucositis industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the oral mucositis industry has stipulated some of the most important medicinal benefits. Major players in the oral mucositis market, including Himalaya Drug Company, Innovation Pharmaceuticals, AMAG Pharmaceutical Inc, Shoreline Pharmaceuticals Inc, Izun Pharmaceuticals Corporation, and others, are funding operations for research and development to boost market demand.

EVERSANA is a creator and operator of an integrated and independent commercial services platform that addresses life science price, access, reimbursement, adherence, and product delivery concerns. The company provides pharmaceutical companies with clinical trial recruiting, extensive patient support, and drug safety, consulting, and management services. In March 2023, Eversana partnered with ChemoMouthpiece to help the latter's medical gadget for oncology patients' US launch and commercialization. The Chemo Mouthpiece is an intraoral ice pack that assists cancer patients in managing and treating oral mucositis. The gadget is intended to administer cryotherapy to the oral cavity of chemotherapy patients.

Sinopia is a biotechnology startup that aims to identify and advance novel therapies by leveraging a multi-omics-powered artificial intelligence/machine learning drug discovery platform. The company's platform enables high-throughput screening and profiling by bridging in vitro to in vivo translation gaps, and it has successfully uncovered multi-billion dollar therapeutic potential and a novel target for chemo/radiation-induced oral mucositis. In February 2023, Sinopia Biosciences, Inc. was awarded funding from National Institute of Dental and Craniofacial Research, a section of National Institutes of Health in the U.S.A., to fund ongoing research into therapeutic possibilities for treating oral mucositis.

Key Companies in the oral mucositis market include

• Izun Pharmaceuticals Corporation


• Shoreline Pharmaceuticals Inc


• AMAG Pharmaceutical Inc


• Innovation Pharmaceuticals


• Himalaya Drug Company

Oral Mucositis Industry Developments

December 2022:Galera Therapeutics, Inc. has submitted a new drug application (NDA) to the FDA seeking approval of avasopasem manganese (GC4419) for radiotherapy-induced oral mucositis in person with head and neck cancer receiving conventional treatment. The application is backed up by data from 678 patients who participated in the phase 2b GT-201 (NCT02508389) and phase 3 ROMAN (NCT03689712) trials.

February 2021:BrainCool AB, a Swedish medical device innovator and leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, disclosed that U.S. Food and Drug Administration had designated the Cooral System as a "Breakthrough Device" for the prevention of Oral Mucositis (OM).

Oral Mucositis Market Segmentation

Oral Mucositis Cause Outlook

• Chemotherapy


• Radiotherapy


• Hematopoietic Stem Cell Transplantation


• Others

Oral Mucositis End-User Outlook

• Hospitals


• Dental Clinics


• Oncology Hospitals


• Research Institutes

Oral Mucositis Regional Outlook